Showing results (21-30 of 38) with videos related to

Sort By:
Pageof 4
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 17, 2013
An intermediate alemtuzumab schedule reduces the incidence of mixed chimerism following reduced-intensity conditioning hematopoietic cell transplantation for hemophagocytic lymphohistiocytosisRebecca A Marsh, Mi-Ok Kim, Chunyan Liu, et al.
Frontiers in Immunology|January 3, 2022
Case Report: Fatal Complications of BK Virus-Hemorrhagic Cystitis and Severe Cytokine Release Syndrome Following BK Virus-Specific T-CellsElizabeth M Holland, Corina Gonzalez, Elliot Levy, et al.
Transplantation and Cellular Therapy|December 27, 2021
Granulocyte Colony-Stimulating Factor Is Safe and Well Tolerated following Allogeneic Transplantation in Patients with Sickle Cell DiseaseNiketa C Shah, Sweta Bhoopatiraju, Allistair Abraham, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 21, 2012
Unrelated donor cord blood transplantation for children with severe sickle cell disease: results of one cohort from the phase II study from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN)Naynesh R Kamani, Mark C Walters, Shelly Carter, et al.
Pediatric Blood & Cancer|March 9, 2017
Team-based approach to identify cardiac toxicity in critically ill hematopoietic stem cell transplant recipientsChristopher E Dandoy, Sonata Jodele, Zachary Paff, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 14, 2015
Experience with Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning Hematopoietic Cell Transplantation in Patients with Nonmalignant Diseases Reveals Good Outcomes and That the Risk of Mixed Chimerism Depends on Underlying Disease, Stem Cell Source, and Alemtuzumab RegimenRebecca A Marsh, Marepalli B Rao, Aharon Gefen, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 29, 2018
Unrelated Donor Transplantation in Children with Thalassemia using Reduced-Intensity Conditioning: The URTH TrialShalini Shenoy, Mark C Walters, Alex Ngwube, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 16, 2018
Immune Reconstitution and Infection Patterns after Early Alemtuzumab and Reduced Intensity Transplantation for Nonmalignant Disorders in Pediatric PatientsSima T Bhatt, Jeffrey J Bednarski, Julia Berg, et al.
Nature Medicine|May 26, 2025
Lentiviral gene therapy with reduced-intensity conditioning for sickle cell disease: a phase 1/2 trialMichael Grimley, Stella M Davies, Archana Shrestha, et al.
Bone Marrow Transplantation|February 21, 2024
Overlap chronic GVHD is associated with adverse survival outcomes compared to classic chronic GVHDLev Gorfinkel, Sharmila Raghunandan, Benjamin Watkins, et al.
Pageof 4